NCT05627245 2026-03-18Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted TreatmentNational Cancer Institute (NCI)Phase 1 Active not recruiting48 enrolled